Bresalier 2005.

Methods	RCT comparing rofecoxib versus placebo for the prevention of colorectal adenoma.
Data	A total of 3260 patients were screened for the study, of whom 2586 were deemed to be eligible (1287/1299 were randomised respectively in each treatment group).
Comparisons	Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment.
Outcomes	The outcome selected was the total number of thrombotic cardiovascular events.
Notes
Risk of bias
Item	Authors' judgement	Description
Method for selecting cases to adjudicate?	No	All suspect events adjudicated were identified by onsite assessor who was blinded to allocated treatment.